Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Saved in:
| Title: | Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. |
|---|---|
| Authors: | Khoo SH; Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK; Tropical and Infectious Disease Unit, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK. Electronic address: khoo@liverpool.ac.uk., FitzGerald R; Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK., Saunders G; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Middleton C; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Ahmad S; NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK., Edwards CJ; Human Development and Health School, University of Southampton, Southampton, UK; NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Hadjiyiannakis D; NIHR Lancashire Clinical Research Facility, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK., Walker L; Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK., Lyon R; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK., Shaw V; Clinical Directorate, University of Liverpool, Liverpool, UK., Mozgunov P; MRC Biostatistics Unit, University of Cambridge, Cambridge, UK., Periselneris J; NIHR Kings Clinical Research Facility, King's College Hospital NHS Foundation Trust, London, UK., Woods C; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK., Bullock K; Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK., Hale C; NIHR Royal Liverpool and Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK., Reynolds H; Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK., Downs N; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Ewings S; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Buadi A; NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Cameron D; NIHR Lancashire Clinical Research Facility, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK., Edwards T; Centre for Drugs and Diagnostics, Liverpool, UK., Knox E; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Donovan-Banfield I; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK; National Institute of Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK., Greenhalf W; Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK., Chiong J; Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK., Lavelle-Langham L; Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK., Jacobs M; Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK., Northey J; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK., Painter W; Ridgeback Biotherapeutics, Miami, FL, USA., Holman W; Ridgeback Biotherapeutics, Miami, FL, USA., Lalloo DG; Liverpool School of Tropical Medicine, Liverpool, UK., Tetlow M; Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK., Hiscox JA; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK; National Institute of Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK., Jaki T; MRC Biostatistics Unit, University of Cambridge, Cambridge, UK; Computational Statistics, University of Regensburg, Regensburg, Germany., Fletcher T; Tropical and Infectious Disease Unit, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK; Clinical Sciences, Liverpool, UK., Griffiths G; Southampton Clinical Trials Unit, University of Southampton, Southampton, UK. |
| Corporate Authors: | AGILE CST-2 Study Group |
| Source: | The Lancet. Infectious diseases [Lancet Infect Dis] 2023 Feb; Vol. 23 (2), pp. 183-195. Date of Electronic Publication: 2022 Oct 19. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
